ABSTRACT
Objetivo: Avaliar a relação de custo-efetividade de mirabegrona como tratamento de primeira escolha de pacientes adultos com síndrome da bexiga hiperativa (SBH) comparada a antimuscarínicos orais comumente prescritos no manejo dessa condição. Métodos: O modelo de Markov foi utilizado, com ciclos mensais e horizonte temporal de um ano, para analisar a relação de custo-efetividade de mirabegrona em comparação a tolterodina, oxibutinina, darifenacina e solifenacina. Os pacientes iniciaram o modelo em tratamento com mirabegrona ou um dos comparadores, sendo distribuídos em cinco níveis de gravidade da doença, de acordo com a frequência miccional e número de episódios de incontinência, e a cada ciclo mensal poderiam melhorar, piorar ou permanecer no mesmo nível de severidade do ciclo anterior. Os resultados foram apresentados por meio de uma razão de custo-efetividade incremental. Resultados: Considerando a perspectiva do sistema de saúde suplementar, o custo total do tratamento com mirabegrona foi de R$ 2.455,26 e os parâmetros de efetividade em 0,491 e 0,498 (melhora na gravidade da incontinência e frequência miccional, respectivamente), sendo mais efetivo que os comparadores. Com relação à perspectiva pública, foi estimado um custo com o tratamento de R$ 1.396,01, com características similares de efetividade. De maneira geral, o tratamento com mirabegrona foi dominante quando comparado à tolterodina e custo-efetivo na comparação com os demais antimuscarínicos, em ambas as perspectivas analisadas. Conclusão: Mirabegrona demonstrou ser a melhor opção para tratamento de primeira escolha da SBH com potencial de redução de custos ao longo do tempo, tanto para o sistema público quanto para o sistema de saúde suplementar brasileiro.
Objective: To assess the cost-effectiveness of mirabegron as first-choice treatment in adult patients with of overactive bladder (OAB) compared to oral antimuscarinics, usually prescribed for this condition. Methods: A Markov model has been adopted, with monthly cycles and a one-year time horizon, to analyze the cost-effectiveness of mirabegron compared to antimuscarinic agents: tolterodine; oxybutynin; darifenacin; and solifenacin. The model started with patients receiving treatment with mirabegron or one of the comparators and then, they were assigned to five disease severity levels according to micturition frequency and number of incontinence episodes, and within each monthly cycle they could improve, worsen or remain at the same symptom severity level. Results were presented using an incremental cost-effectiveness ratio. Results: Considering the Brazilian private perspective, treatment with mirabegron resulted in a total cost of R$ 2,455.26 and effectiveness parameters at 0.491 and 0.498 (improvement in incontinence severity and micturition, respectively), being more effective than the comparators. Regarding the Brazilian public perspective, treatment with mirabegron resulted in a total cost of R$ 1,396.01 with similar effectiveness estimation. In general, a dominance was observed when mirabegron was compared to tolterodine and a cost-effectiveness profile against the other muscarinic antagonists, considering both health perspectives. Conclusion: Mirabegron has proven to be the best option for OAB first-line treatment with potential cost savings over time for both the public and private health care systems in Brazil.
Subject(s)
Urinary Bladder , Cost-Benefit Analysis , Adrenergic beta-Agonists , Muscarinic Antagonists , Urinary Bladder, OveractiveABSTRACT
Al enfrentarnos a casos que tienen relación con tumores de cabeza y cuello, hay que tener en cuenta la gran diversidad de presentaciones de las neoplasias, histopatología y topografía anatómica de las mismas. Sumado a esto intervendrán factores etiológicos o de riesgo, que darán distintas características epidemiológicas, sintomatológicas, tanto en la forma de progresión de la enfermedad, como en su pronóstico y plan de tratamiento. En este trabajo los autores presentan un caso clínico de una paciente femenino de 25 años con una maxilectomia, por mixoma odontogénico, en su variable histológica de Fibromixoma Odontogénico, ubicado en el seno maxilar derecho. El tratamiento rehabilitador protésico, se realiza con una prótesis obturatriz esquelética, preparando los pilares paralelizados, con los principios de un eje único y preciso de inserción y retiro...
When dealing with neck and head cancer patients, we must consider the many different types of such tumors that appear when conducting histopathologic and anatomic topography assessment. To this we must add etiological or risk factors that will result in various epidemiological and symptomatological characteristics, both regarding the progression of the disease and the prognosis and treatment plan. In this work a clinical case is presented: a 25-year-old female patient who underwent right maxillectomy for an odontogenic myxoma (fibromyxoma) located in her right maxillary sinus. Prosthetic rehabilitation is done with framework obturator prosthesis. The remaining teeth are prepared by creating parallel pillars to obtain a single and accurate axis for insertion and removal...
Subject(s)
Humans , Maxillofacial Prosthesis Implantation , Maxillary Neoplasms/surgery , Maxillofacial ProsthesisABSTRACT
Introduction: Painful bladder syndrome/interstitial cystitis (PBS/IC) pathogenesis is not fully known, but evidence shows that glycosaminoglycans (GAG) of bladder urothelium can participate in its genesis. The loss of these compounds facilitates the contact of urine compounds with deeper portions of bladder wall triggering an inflammatory process. We investigated GAG in urine and tissue of PBS/IC and pure stress urinary incontinence (SUI) patients to better understand its metabolism. Materials and Methods: Tissue and urine of 11 patients with PBS/IC according to NIDDK criteria were compared to 11 SUI patients. Tissue samples were analyzed by histological, immunohistochemistry and immunofluorescence methods. Statistical analysis were performed using t Student test and Anova, considering significant when p < 0.05. Results: PBS/IC patients had lower concentration of GAG in urine when compared to SUI (respectively 0.45 ± 0.11 x 0.62 ± 0.13 mg/mg creatinine, p < 0.05). However, there was no reduction of the content of GAG in the urothelium of both groups. Immunofluorescence showed that PBS/IC patients had a stronger staining of TGF-beta, decorin (a proteoglycan of chondroitin/dermatan sulfate), fibronectin and hyaluronic acid. Conclusion: the results suggest that GAG may be related to the ongoing process of inflammation and remodeling of the dysfunctional urothelium that is present in the PBS/IC. .
Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Cystitis, Interstitial/metabolism , Glycosaminoglycans/metabolism , Urinary Incontinence, Stress/metabolism , Biopsy , Creatinine/urine , Cystitis, Interstitial/pathology , Fluorescent Antibody Technique , Glycosaminoglycans/analysis , Hyaluronic Acid/urine , Immunohistochemistry , Real-Time Polymerase Chain Reaction , Urinary Bladder/pathology , Urinary Incontinence, Stress/pathology , Urothelium/metabolism , Urothelium/pathologyABSTRACT
La rehabilitación integral del paciente mutilado facial implica un gran desafío, el poderle brindar un tratamiento económicamente accesible y en el mismo medio donde el paciente vive es de importancia capital.Independientemente de la cobertura de salud que el paciente tenga, de su nivel socioeconómico ó de su lugar de residencia en el territorio nacional.El objetivo de este artículo es la divulgación de los logros alcanzados en la descentralización de la Prótesis Buco Maxilo Facial en nuestro País, fruto del trabajo conjunto entre dos Instituciones, la Universidad de la República y la Administración de los Servicios de Salud del Estado.
The rehabilitation of facial maimed patients, means a great challenge. The chance to provide accessible and economic care in the same environment where the patient lives, is paramount, regardless the health coverage the patient might have, his socioeconomic status residence place in the country.The aim of this article is the dissemination of the achievements of the decentralization of Maxillofacial Prosthetics care, that is a joint work between of two institutions, the University of the Republic and the Administration of State Health Services.
Subject(s)
Politics , Maxillofacial Prosthesis , Local Health SystemsABSTRACT
PURPOSE: We reproduced a non-bacterial experimental model to assess bladder inflammation and urinary glycosaminoglycans (GAG) excretion and examined the effect of dimethyl sulfoxide (DMSO). MATERIALS AND METHODS: Female rats were instilled with either protamine sulfate (PS groups) or sterile saline (control groups). At different days after the procedure, 24 h urine and bladder samples were obtained. Urinary levels of hyaluronic acid (HA) and sulfated glycosaminoglycans (S-GAG) were determined. Also to evaluate the effect of DMSO animals were instilled with either 50 percent DMSO or saline 6 hours after PS instillation. To evaluate the effect of DMSO in healthy bladders, rats were instilled with 50 percent DMSO and controls with saline. RESULTS: In the PS groups, bladder inflammation was observed, with polymorphonuclear cells during the first days and lymphomononuclear in the last days. HA and S-GAG had 2 peaks of urinary excretion, at the 1st and 7th day after PS injection. DMSO significantly reduced bladder inflammation. In contrast, in healthy bladders, DMSO produced mild inflammation and an increase in urinary HA levels after 1 and 7 days and an increase of S-GAG level in 7 days. Animals instilled with PS and treated with DMSO had significantly reduced levels of urinary HA only at the 1st day. Urinary S-GAG/Cr levels were similar in all groups. CONCLUSIONS: Increased urinary levels of GAG were associated with bladder inflammation in a PS-induced cystitis model. DMSO significantly reduced the inflammatory process after urothelial injury. Conversely, this drug provoked mild inflammation in normal mucosa. DMSO treatment was shown to influence urinary HA excretion.